Genmab A/S Files 6-K Report
Ticker: GNMSF · Form: 6-K · Filed: Apr 3, 2024 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Apr 3, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-K, registration-statement
TL;DR
Genmab filed a 6-K, incorporating it into existing S-8 filings. Standard update.
AI Summary
Genmab A/S filed a Form 6-K on April 3, 2024, to report information for the month of April 2024. This filing is incorporated by reference into several of Genmab's S-8 registration statements, including File Nos. 333-232693, 333-253519, 333-262970, and 333-277273.
Why It Matters
This filing serves as an update for investors and indicates ongoing reporting requirements for Genmab A/S with the SEC.
Risk Assessment
Risk Level: low — This filing is a routine report and does not contain new financial results or significant operational updates that would typically increase risk.
Key Players & Entities
- Genmab A/S (company) — Registrant
- 333-232693 (dollar_amount) — S-8 Registration Statement File Number
- 333-253519 (dollar_amount) — S-8 Registration Statement File Number
- 333-262970 (dollar_amount) — S-8 Registration Statement File Number
- 333-277273 (dollar_amount) — S-8 Registration Statement File Number
FAQ
What type of SEC filing is this?
This is a Form 6-K report, which is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
What is the filing date of this report?
The filing date is April 3, 2024.
Which company filed this report?
Genmab A/S filed this report.
What is the primary purpose of this Form 6-K filing?
This filing is to report information for the month of April 2024 and is incorporated by reference into Genmab A/S's registration statements on Form S-8.
What are the file numbers of the Genmab A/S registration statements mentioned in the filing?
The mentioned file numbers for Genmab A/S's S-8 registration statements are 333-232693, 333-253519, 333-262970, and 333-277273.
Filing Stats: 226 words · 1 min read · ~1 pages · Grade level 15 · Accepted 2024-04-03 06:19:30
Filing Documents
- tmb-20240403x6k.htm (6-K) — 18KB
- tmb-20240403xex99d1.htm (EX-99.1) — 41KB
- tmb-20240403xex99d1001.jpg (GRAPHIC) — 5KB
- tmb-20240403xex99d1002.jpg (GRAPHIC) — 5KB
- 0001558370-24-004638.txt ( ) — 74KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S's registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970 and 333-277273 ) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. nthony GENMAB A/S BY: /s/ Anthony Pagano Name: Anthony Pagano Title: Executive Vice President & Chief Financial Officer DATE: April 3, 2024 EXHIBIT INDEX O Exhibit Description of Exhibit 99.1 Company Announcement Dated April 3, 2024: Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio